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Preclinical studies suggest that ketamine-induced psychopathology is mediated, in part, by 
increased glutamate release, hypothesized to occur via inhibition of GABAergic interneurons. 
Using proton magnetic resonance spectroscopy, we tested this hypothesis in healthy humans.  
Ketamine increased anterior cingulate cortex glutamate levels, which correlated with the 
degree of positive psychotic symptoms. Ketamine did not affect subcortical GABA levels. 
 
Ketamine, an uncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, induces 
perceptual and behavioral responses resembling the positive, negative and cognitive symptoms of 
schizophrenia.1  In rodents increases in cortical glutamate have been shown following acute 
systemic ketamine administration, as measured by microdialysis,2 and also following chronic 
ketamine administration, as measured by proton magnetic resonance spectroscopy (1H-MRS).3 In 
humans, increased glutamine levels in anterior cingulate have been detected using 1H-MRS 
following ketamine administration.4 Ketamine has been suggested to increase cortical glutamate 
release through inhibition of GABAergic interneurons,5 possibly in thalamus.6 In this study we used 
1H-MRS to test the hypothesis that ketamine administration in humans reduces subcortical GABA 
levels and increases cortical glutamate and glutamine levels, and that these changes are related to 
ketamine-induced psychotic symptoms. 
 
Methods are fully described in supplemental materials. Briefly, 1H-MRS data were acquired, using 
a 3 Tesla magnetic resonance imaging system, from 13 healthy male volunteers. GABA edited MR-
spectra using the MEGA-PRESS method were acquired from a 30x30x30mm volume positioned 
medially over the thalami (bilaterally) and surrounding subcortical structures (see supplementary 
figure S1), followed by a PRESS acquisition (TE=30), to estimate glutamate levels, acquired from a 
20x20x20mm midline volume positioned over the anterior cingulate 13mm above the genu of 
corpus callosum (see supplementary figure S2). A dynamically modeled intravenous infusion of 
ketamine was commenced (target plasma level: 150ng/mL), and the GABA and glutamate 
acquisitions were repeated at 25 and 35 minutes after the start of the infusion respectively. After 
completing the scan, ketamine-induced effects were measured using the positive and negative 
syndrome scale (PANSS). 
 
1H-MRS data were corrected for voxel CSF and water content. Normality of data was checked 
using the Shapiro-Wilk test. Changes in anterior cingulate glutamate and in subcortical GABA were 
analysed using paired t-tests. Correlations between metabolite levels and PANSS scores were 
analysed using Pearson's product moment correlation coefficient. 
 
Following ketamine administration, mean(SD) PANSS positive, negative and general subscales 
increased to 10.7(2.89), 10.07(3.43) and 20.15(3.53) respectively. Anterior cingulate glutamine 
quantification was of reasonable quality (Cramer-Rao Mean Variance Bounds < 20%) in only 27% 
of scans, and so data were insufficient to examine whether ketamine had any effect on this 
metabolite. Ketamine led to a significant increase in glutamate in anterior cingulate (t=3.11, df=12, 
p=0.009; fig 1), but did not affect anterior cingulate glutamate+glutamine, or subcortical GABA 
levels (see supplementary table S1). Anterior cingulate glutamate following ketamine 
administration was significantly related to PANSS positive (r=0.72, p=0.005; fig 1), but not PANSS 
negative or general subscales. PANSS subscales were not related to baseline anterior cingulate 
glutamate levels nor to GABA levels at either time-point. 
 
This study provides support for the hypothesis that ketamine leads to increases in glutamatergic 
neurotransmission in anterior cingulate cortex. One limitation is the lack of placebo-control. 
However, our results are in keeping with the finding of increased glutamate in frontal cortex in rats 
following ketamine administration,3 and converge with an earlier finding of increased glutamine in 
anterior cingulate in the first 10 minutes following ketamine administration in humans.4 It has been 
suggested that increased glutamine may be the first marker of increased glutamate release, with  
increases in glutamate becoming detectable as glutamine is converted back to glutamate,3 which 
may explain the difference between our finding and that of Rowland et al. The lack of an effect of 
ketamine on subcortical GABA is in keeping with an earlier study which failed to show any effect 
of ketamine on glutamate or GABA levels in occipital cortex,7 but it is possible that ketamine 
effects on GABA neuron activity occur at an earlier time-point or in a different brain region. 
 
Increased glutamate transmission, as indexed by glutamine levels in anterior cingulate, has been 
reported in individuals at risk of psychosis and in patients with first episode schizophrenia,8, 9 
whereas in depression, reduced glutamate levels are generally reported.10 The current study suggests 
that ketamine-induced psychological effects may share a common neurochemical basis with 
idiopathic psychoses and that  increases in glutamatergic neurotransmission may underlie 
ketamine's antidepressant effect. 
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Figure 1: glutamate levels in anterior cingulate before and after ketamine (A; p=0.009), and 
relationship of anterior cingulate glutamate levels to PANSS positive scores following ketamine 
administration (B; p=0.006). 
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Supplementary materials 
Methods 
The study was approved by the East London Research Ethics Committee, UK.  Healthy male 
volunteers were recruited by advertising. After the purpose of the study was explained to them 
verbally and in writing, they were invited to come for a screening assessment where, after giving 
written informed consent to be included in the study, they were assessed for their suitability for the 
study according to the following inclusion and exclusion criteria: 
 
Inclusion criteria: 
1. Healthy right−handed male subjects between the ages of 18 and 50 years, inclusive (healthy is 
defined as no clinically relevant abnormalities identified by a detailed medical history and full 
physical examination, including blood pressure, pulse rate measurement and 12−lead ECG).   
2. Body Mass Index (BMI) of 18 to 30 Kg/m2; and a total body weight 50−100 kg.  
 
Exclusion criteria: 
1. Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, 
gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including 
drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). This 
also includes subjects with previous history of epilepsy or seizures, psychiatric illness, attempted 
suicide or suicidal ideation, or glaucoma.   
2. Use of prescription or non−prescription drugs within 7 days or 5 half−lives with the exception of 
paracetamol (acetaminophen). 
3. History of sensitivity to ketamine. 
4. History of febrile illness within 5 days prior to the first dose.   
5. 12−lead ECG demonstrating QTc >430 msec at screening.   
6. Fulfillment of any of the MRI contraindications on the standard radiography screening 
questionnaire. 
7. History of regular alcohol consumption exceeding 28 drinks/week (1 drink = 5 ounces (150 mL) 
of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of spirits) within 6 months of 
screening.   
8. Use of tobacco− or nicotine−containing products in excess of the equivalent of 5 cigarettes per 
day.   
9. A positive urine drug screen for drugs of abuse. 
 
Thirteen male volunteers were included in the study. In order to assess their eligibility for the study, 
they underwent psychiatric and medical history, mental state, and physical examination (by clinical 
psychiatrists - JS or CD). Investigations included electrocardiogram (ECG), urine drug screen, 
weight, temperature and blood pressure. They were cannulated in the left antecubital fossa, and 
connected via a venous line to a computer-controlled pump-driver, with a 50ml syringe containing 
4mg/ml racemic ketamine. 
 
All volunteers underwent MRI imaging on a General Electric (Milwaukee, Wisconsin) 3-Tesla HDx 
magnetic resonance system. Subjects underwent an initial localizer scan followed by acquisition of 
structural images including an axial 2D T2-weighted fast spin echo scan and an axial fast fluid-
attenuated inversion recovery scan (total scan time = 5 min). These were followed by a whole-brain 
three-dimensional coronal inversion recovery prepared spoiled gradient echo (IR-SPGR) scan, 
giving isotropic 1.1-mm voxels in a scan time of approximately 6 min (echo time (TE) = 2.82 msec; 
repetition time (TR) = 6.96 msec; inversion time = 450 msec; excitation flip angle = 20°).  
 
GABA-edited proton magnetic resonance spectroscopy (1H-MRS) was performed using the 
MEGA-PRESS method,1, 2 from a 30×30×30mm volume positioned medially over the thalami 
(bilaterally) and surrounding subcortical structures. This method has been shown to have good test-
retest reliability for measuring GABA (R2=0.999),3 with a coefficient of variance of 7%.4  To 
visualise the thalami, the IR-SPGR scan was reformatted into an orientation orthogonal to the 
posterior border of the pons. The MEGA-PRESS voxel was then prescribed on the slice of this 
reformatted image in which the thalamus was widest, with its left/right position centred on the 
midline of the brain and its anterior/posterior position determined by the thalami (Figure S1). 
MEGA-PRESS parameters were: TE=68ms; TR= 1800ms; 16ms Gaussian editing pulse applied at 
1.9ppm (ON scans) and 7.5ppm (OFF scans) in an interleaved fashion (332 averages). Four-hertz 
exponential line broadening was used and the MEGA-PRESS difference spectrum produced.  
Finally, a high-pass water filter was applied. As the unsuppressed water was small in the difference 
spectra, applying this filter did not substantially disturb the baseline at 3ppm. 
 
Following this, all subjects underwent PRESS (Point RESolved Spectroscopy) 1H-MRS – a method 
with with good test-retest reliability (R2=0.987) for measuring glutamate.3. PRESS data (TE = 30 
msec; TR = 3000 msec; 96 averages) were acquired using the standard GE PROBE (proton brain 
examination) sequence, which uses a standardized chemically selective suppression (CHESS) water 
suppression routine.  Shimming (using first order shims only) was optimized, with auto-prescan 
performed twice before each scan. The anterior cingulate ROI was prescribed from the midline 
sagittal localiser, and the centre of the 20mm x 20mm x 20mm ROI was placed 13mm above the 
anterior section of the Genu of Corpus Callosum at 90o to the AC-PC line (Figure S2). 
 
Unsuppressed water reference spectra (16 averages) were acquired from the same brain regions as 
part of the standard PRESS and MEGA-PRESS acquisitions. 
 
A dynamically modeled intravenous infusion of ketamine was commenced (target plasma level: 
150ng/mL).  The rate of infusion was controlled over the full period of infusion by a laptop 
computer running Stanpump software [available free of charge from Dr S. Shafer MD at 
http://anesthesia.stanford.edu/pkpd/ (accessed September 2011)] driving a Graseby 3400 syringe-
driver. The rate was determined based on the pharmacodynamic properties of ketamine from the 
“Clements 250 model”.5, 6 In practice, this translated to a rapid bolus over 20 seconds of approx. 
0.26mg/Kg followed by a slow infusion of approx. 0.42mg/Kg/Hr (Figure S3). 
 
The MEGA-PRESS and PRESS 1H-MRS acquisitions were repeated at 25 and 35 minutes after the 
start of the infusion respectively. The time points and sequence of the PRESS and MEGA-PRESS 
acquisitions were chosen on the basis of microdialysis data 7, which demonstrated that changes in 
cortical extracellular glutamate levels were relatively slow, increasing at 20-40 minutes post-
injection, and peaking around 120 minutes. We hypothesized that, if changes in GABA gave rise to 
downstream  effects on glutamate transmission, they would be detectable before glutamate 
increases, and so positioned the MEGA-PRESS acquisition just before the PRESS. 
 
Each scanning session concluded with the collection of a PRESS spectrum from a phantom 
containing standard concentrations of brain metabolites to allow monitoring of the effect of scanner 
drift on 1H-MRS metabolite estimates. There was no significant effect of scanner drift for the 
duration of the study, and therefore, no corrections were required. 
 
Rating Scales 
After completing the scan, the ketamine infusion was stopped, and volunteers were interviewed in 
an adjoining room about their experiences during the infusion. Subjective descriptions of the 
strongest effects during the infusion were elicited. Ketamine-induced effects were measured using 
the positive and negative syndrome scale (PANSS),8 by JS. 
 
1H-MRS quantification 
MEGA-PRESS data were analysed with in-house software developed using Matlab (Figure S4). 
The edited GABA signal at 3 ppm in the MEGA PRESS difference spectrum, and the unsuppressed 
water signal from the same region were integrated. The integral of the GABA peak was calculated 
automatically using a linear fit of the baseline and a Gaussian fit to the peak itself , as we have used 
previously.9-13 The water lineshape was modeled as a mixed Gaussian-Lorentzian lineshape.14 
Adequate MEGA-PRESS spectrum quality was confirmed by visual inspection. A concentration 
measurement in institutional units was derived by accounting for the editing efficiency and the T1 
and T2 relaxation times of water and GABA, using published values for the metabolite relaxation 
times.15-19 
 
PRESS spectra (Figure S5) were analyzed using LCModel version 6.1-4 F.20 The raw spectral data 
were read into LCMgui, the graphical user interface for LCModel, which automatically combined 
the data from the eight-channel coil with a weighted coherent average over the eight receive 
channels using the intensity of the first point of the Free Induction Decay of the unsuppressed water 
reference from each coil. A standard basis set of 16 metabolites (L-alanine, aspartate, creatine, 
phosphocreatine, GABA, glucose, glutamine, glutamate, glycerophosphocholine, glycine, myo-
inositol, L-lactate, N-acetylaspartate, N-acetylaspartylglutamate, phosphocholine, taurine), included 
as part of LCModel and acquired with the same field strength (3-T), localization sequence (PRESS), 
and echo time (30 msec) as our study was used. Model metabolites and concentrations employed in 
the basis set are fully detailed in the LCModel manual (http://s-provencher.com/pages/lcm-
manual.shtml). For all metabolites we used the recommended cut-off of Cramer-Rao minimum 
variance bounds (CRMVB) of 20% to exclude poorly fitted metabolite peaks. 
 
The IR-SPGR scans were used for localization of the spectroscopy voxels and were segmented into 
grey matter, white matter and cerebrospinal fluid (CSF) using Statistical Parametric Mapping 8 
software (SPM8; Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University 
College London, United Kingdom) to allow correction of water-scaled  metabolite values for partial 
volume CSF contamination. Voxel CSF, grey- and white-matter content was determined from the 
voxel location using in-house software. Metabolite values were corrected for the presence of CSF in 
the voxel using the formula Mcorr = M/(wm +gm), where M is the uncorrected metabolite value, 
and wm and gm are the white and grey matter fractions from the segmented images (ranging 
between 0 and 1) for the spectroscopy voxel. Since the metabolite measures were derived with 
water-scaling, a further correction was applied to correct the estimated water concentration of the 
voxel for partial volume CSF contamination. We used the same default CSF and brain water 
concentrations employed by LCModel (55,556 mol/m3 and 35,880 mol/m3 respectively; http://s-
provencher.com/pages/lcm-manual.shtml). For practical purposes, these two correction factors were 
combined into a single equation (Mcorr = M / (35,880 * (wm+gm)/(35,880 * (wm+gm) + 55,556 * 
CSF)), where CSF is the fraction of the voxel filled with cerebrospinal fluid, which simplifies to 
Mcorr = M*(wm+gm + 1.55CSF) / (wm+gm). 
 
Statistics 
Normality of data was checked using the Shapiro-Wilk test. Changes in metabolite levels with 
ketamine administration were analysed using paired t-tests. Correlations between metabolite levels 
and PANSS scores were analysed using Pearson's product moment correlation coefficient. 
 
Figure S1: Position of MEGA-PRESS voxel 
 
 
 
 
 
 
 
 
 
Figure S2: Position of PRESS voxel. 
 
 
 
 
 
 
 
Figure S3: Representative plot of volume infused (mL) vs. time (10s increments). 4mg/mL racemic 
ketamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Sample pre- and post-ketamine (left and right column respectively) MEGA-PRESS 
spectra from 3 participants. 
 
Figure S5: Sample pre- and post-ketamine (left and right column respectively) PRESS spectra 
(LCModel output) from 3 participants. 
 
Table S1: Cramer-Rao Mean Variance Bounds (%CRMVB) in anterior cingulate (glutamate, 
glutamine) and thalamus (GABA) for all subjects. Brain metabolite levels (mean(SD) 
including data where individual CRMVB<20%) before and after ketamine administration    
(* paired p<0.01) are also presented. All values are reported as i.u. 
 Pre-ketamine Post-ketamine 
 Mean(SD) 
%CRMVB 
reported 
by 
LCModel  
Mean(SD) 
linewidth of 
water 
reported by 
scanner (Hz) 
Mean(SD) 
metabolite 
levels 
Mean(SD) 
%CRMVB 
reported by 
LCModel  
Mean(SD) 
linewidth of 
water 
reported by 
scanner (Hz) 
Mean(SD) 
metabolite 
levels 
Anterior Cingulate 
Glutamate 
9.8(1.5) 
n=13 
5.7(0.8) 
n=13 
12.4(1.78) 
n=13 
8.2(2.5) 
n=13 
5.53(0.52) 
n=13 
14.0(2.31) * 
n=13 
Anterior Cinglulate 
Glutamine 
34.3(24.1) 
n=12 
5.7(0.8) 
n=13 
9.3(1.51) 
n=3 
26.9(15.0) 
n=12 
5.53(0.52) 
n=13 
9.69(0.94) 
n=4 
Anterior Cingulate 
Glutamate+Glutamine 
10(1.8) 
n=13 
5.7(0.8) 
n=13 
17.5(4.1) 
n=13 
11.3(1.7) 
n=13 
5.53(0.52) 
n=13 
19.7(3.86) 
n=13 
Thalamus GABA N/A 11.1(2.23) 
n=13 
33.7(4.8) 
n=13 
N/A 11.5(3.0) 
n=13 
34.0(6.1) 
n=13 
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